The Dopamine D3 Receptor Antagonist VK4-40 Attenuates Morphine-Induced Hyperactivity But Not Cocaine-Induced Hyperactivity in Mice by Pulley, Desta M. et al.
Rowan University 
Rowan Digital Works 
Stratford Campus Research Day 25th Annual Research Day 
May 6th, 12:00 AM 
The Dopamine D3 Receptor Antagonist VK4-40 Attenuates 
Morphine-Induced Hyperactivity But Not Cocaine-Induced 
Hyperactivity in Mice 
Desta M. Pulley 
Rowan University 




Follow this and additional works at: https://rdw.rowan.edu/stratford_research_day 
 Part of the Cell Biology Commons, Disease Modeling Commons, Medical Cell Biology Commons, 
Molecular and Cellular Neuroscience Commons, Neurosciences Commons, and the Substance Abuse and 
Addiction Commons 
Let us know how access to this document benefits you - share your thoughts on our feedback 
form. 
Pulley, Desta M.; Debski, Jessica J.; and Manvich, Daniel, "The Dopamine D3 Receptor Antagonist VK4-40 
Attenuates Morphine-Induced Hyperactivity But Not Cocaine-Induced Hyperactivity in Mice" (2021). 
Stratford Campus Research Day. 78. 
https://rdw.rowan.edu/stratford_research_day/2021/may6/78 
This Poster is brought to you for free and open access by the Conferences, Events, and Symposia at Rowan Digital 
Works. It has been accepted for inclusion in Stratford Campus Research Day by an authorized administrator of 
Rowan Digital Works. 
The Dopamine D3 Receptor Antagonist VK4-40 Attenuates Morphine-Induced 
Hyperactivity but not Cocaine-Induced Hyperactivity in Mice
Desta M. Pulley, Jessica J. Debski, Daniel F. Manvich
Department of Cell Biology and Neuroscience, Rowan University School of Osteopathic Medicine, Stratford, NJ 
In light of the increasing rates of opioid abuse in the US, the search for viable
medications to treat opioid abuse disorder (OUD) has become ever more
urgent. Opioids exert their abuse-related effects in part by indirectly increasing
dopamine (DA) neurotransmission in the mesolimbic system, a dopaminergic
projection arising in the ventral tegmental area and terminating in the nucleus
accumbens. The DA D3 receptor (D3R), which belongs to the D2 family of
dopamine receptors (D2, D3 , D4 receptor subtypes), is highly expressed in
these brain regions and has shown strong potential as a pharmacotherapeutic
target for the treatment of OUD. More specifically, D3R antagonists have been
shown by us and others to attenuate the abuse-related behavioral effects of
opioids without producing adverse side effects associated with nonselective
D2-like receptor antagonists.
We previously examined the effects of the selective D3R antagonist PG01037
(133-fold selectivity for D3R vs. D2R) using drug-induced hyperactivity as a
behavioral proxy for DA release within the nucleus accumbens. Interestingly,
we found that PG01037 enhances cocaine-induced hyperlocomotion while it
attenuates morphine-induced hyperlocomotion in mice. The potentiation of
psychostimulant effects could confound the potential use of D3R antagonists
for the treatment of OUD, since many opioid users co-abuse stimulants such
as cocaine. However, recent studies with more selective D3R antagonists
found that they do not enhance certain effects of cocaine while still reducing
opioid effects. It is currently unknown what impact these highly-selective D3R
antagonists will have on cocaine-induced hyperactivity and/or dopamine
neurotransmission.
The purpose of this study was to examine the impact of pretreatment with the
novel and highly selective D3R antagonist VK4-40 (250-fold selectivity for D3R
vs. D2R) on cocaine- and morphine-induced hyperlocomotion in mice.
Methods
Introduction
16 locomotor activity chambers (above; left. San Diego Instruments; San Diego,
California) were used to measure horizontal locomotion in mice. “Ambulations”
were recorded when a mouse interrupted an infrared beam adjacent to a
previously-interrupted beam in either the x- or y- plane of the chamber (above;
right). Repeated disruptions of the same beam were not counted.
Figure 3. Time course effects of cocaine-induced locomotion following pretreatment with VK4-40. Vehicle, 3, 10, or 20 mg/kg of
VK4-40 was administered 30 min prior to (A) 3 mg/kg cocaine, or (B) 10 mg/kg cocaine. Each data point represents mean ±SEM total
ambulations recorded in 5-min bins.
Proestrus=
Effects of VK4-40 alone
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• VK4-40 dose-dependently attenuates morphine-
induced hyperactivity, but not cocaine-induced 
hyperactivity
• VK4-40 attenuates morphine-induced hyperactivity 
at doses that do not affect basal locomotion
• Highly selective dopamine D3 receptor antagonists 
have potential in treating opioid use disorder 
without enhancing effects of cocaine
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Figure 4. Effects of VK4-40 pretreatment on total ambulations over 120 min following
saline i.p. (n=16). **p=0.001, VK4-40 compared to vehicle. Each data point represents
mean ±SEM total ambulations.
*
VK4-40 selectively attenuates morphine-induced hyperlocomotion
Figure 1. Dose-response showing effects of VK4-40 pretreatment on total ambulations (A) 60 minutes following cocaine injections
(n=16) and (B) 120 minutes following morphine injections (n=16). ***p<0.001, VK4-40 compared to vehicle at 5.6 mg/kg morphine.
****p<0.0001, VK4-40 compared to vehicle at 18 mg/kg morphine. Each data point represents mean ±SEM total ambulations.
Time course: VK4-40 + Cocaine
VK4-40 dose-response (prior to saline)
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• 2 groups of 16 adult C57BL/6J mice (8 male; 8 female) were tested weekly
• Group 1: VK4-40 (veh, 3, 10, 20 mg/kg) and cocaine (3, 10 mg/kg)
• Group 2: VK4-40 (veh, 3, 10, 20 mg/kg) and morphine (0, 5.6, 18 mg/kg)
• 4-hour locomotor activity sessions
• 90 min habituation prior to 1st injection
• 1st injection (VK4-40) followed by 30 min
• 2nd injection (cocaine or morphine) followed by120 min














Time course: VK4-40 + Morphine
Figure 4. Time course effects of morphine-induced locomotion following pretreatment with VK4-40. Vehicle, 3, 10, or 20 mg/kg of
VK4-40 was administered 30 min before (A) 5.6 mg/kg morphine, or (B) 18 mg/kg morphine. Each data point represents mean ±SEM
































































































Vehicle 3.2 10 32
**
Figure 5. Time course effects of locomotion following pretreatment with VK4-40. Vehicle,
3, 10, or 20 mg/kg of VK4-40 was administered 30 min before saline. Each data point
represents mean ±SEM total ambulations recorded in 5-min bins.
VK4-40 attenuates locomotion only at the highest dose
A B
Cocaine dose-response Morphine dose-response
90 min 120 min 240 min
VK4-40 Cocaine or morphine
Ambulations were recorded for 4 h. Cocaine data were analyzed 60 min post-
cocaine injection, whereas morphine was analyzed 120 min post-injection. 
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